Streetbeat News

Price Targets

ELYS

HC Wainwright & Co. analyst Scott Buck has reiterated a 'Buy' rating on Elys Game Technology (NASDAQ:ELYS), but lowered the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:42 am

SHAK

Raymond James analyst Brian Vaccaro has maintained an 'Outperform' rating on Shake Shack (NYSE:SHAK), but lowered the price target from $87 to $78.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:39 am

DRI

Raymond James analyst Brian Vaccaro has maintained an 'Outperform' rating on Darden Restaurants (NYSE:DRI) but lowered the price target from $165 to $155.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:37 am

CMG

Raymond James analyst Brian Vaccaro has maintained an 'Outperform' rating on Chipotle Mexican Grill (NYSE:CMG) but lowered the price target from $2300 to $2100.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:36 am

BLMN

Raymond James analyst Brian Vaccaro has maintained a 'Strong Buy' rating on Bloomin Brands (NASDAQ:BLMN), but lowered the price target from $33 to $29.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:33 am

FWRG

Raymond James analyst Brian Vaccaro has upgraded First Watch Restaurant Gr (NASDAQ:FWRG) from Outperform to Strong Buy, but lowered the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:30 am

EAT

Raymond James analyst Brian Vaccaro has upgraded Brinker International (NYSE:EAT) from Outperform to Strong Buy, but lowered the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:28 am

LEGN

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $85 to $86.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:26 am

MBOT

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Microbot Medical (NASDAQ:MBOT) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:21 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:59 am